oxonic acid has been researched along with Anasarca in 10 studies
Oxonic Acid: Antagonist of urate oxidase.
Excerpt | Relevance | Reference |
---|---|---|
" The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)." | 7.91 | Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019) |
" The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)." | 3.91 | Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019) |
" affine extract was evaluated in an experimental model with potassium oxonate (PO) induced hyperuricemia in mice which was used to evaluate anti-hyperuricemia activity and xanthine oxidase (XO) inhibition." | 3.85 | Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis. ( Cheng, L; Hu, YJ; Li, LN; Liang, WQ; Liu, PG; Pu, JB; Xu, P; Yang, QQ; Zhang, HJ; Zhang, YQ; Zhou, J, 2017) |
"Pancreatic cancer is frequently complicated by malignancies in other organs." | 1.39 | Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. ( Gabata, T; Ikeda, H; Ishikawa, D; Iwakami, S; Matsui, O; Mouri, H; Nanjo, S; Ohtsubo, K; Takamatsu, Y; Takeuchi, S; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (10.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 6 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Zhang, HJ | 1 |
Li, LN | 1 |
Zhou, J | 1 |
Yang, QQ | 1 |
Liu, PG | 1 |
Xu, P | 1 |
Liang, WQ | 1 |
Cheng, L | 1 |
Zhang, YQ | 1 |
Pu, JB | 1 |
Hu, YJ | 1 |
Liang, G | 1 |
Nie, Y | 1 |
Chang, Y | 1 |
Zeng, S | 1 |
Liang, C | 1 |
Zheng, X | 1 |
Xiao, D | 1 |
Zhan, S | 1 |
Zheng, Q | 1 |
Yang, TH | 1 |
Yan, DX | 1 |
Huang, XY | 1 |
Hou, B | 1 |
Ma, YB | 1 |
Peng, H | 1 |
Zhang, XM | 1 |
Chen, JJ | 1 |
Geng, CA | 1 |
Ohtsubo, K | 1 |
Ishikawa, D | 1 |
Nanjo, S | 1 |
Takeuchi, S | 1 |
Yamada, T | 1 |
Mouri, H | 1 |
Yamashita, K | 1 |
Yasumoto, K | 1 |
Gabata, T | 1 |
Matsui, O | 1 |
Ikeda, H | 1 |
Takamatsu, Y | 1 |
Iwakami, S | 1 |
Yano, S | 1 |
Takashima, T | 1 |
Mukai, H | 1 |
Hara, F | 1 |
Matsubara, N | 1 |
Saito, T | 1 |
Takano, T | 1 |
Park, Y | 1 |
Toyama, T | 1 |
Hozumi, Y | 1 |
Tsurutani, J | 1 |
Imoto, S | 1 |
Watanabe, T | 1 |
Sagara, Y | 1 |
Nishimura, R | 1 |
Shimozuma, K | 1 |
Ohashi, Y | 1 |
Silva, CR | 1 |
Fröhlich, JK | 1 |
Oliveira, SM | 1 |
Cabreira, TN | 1 |
Rossato, MF | 1 |
Trevisan, G | 1 |
Froeder, AL | 1 |
Bochi, GV | 1 |
Moresco, RN | 1 |
Athayde, ML | 1 |
Ferreira, J | 1 |
Makari, Y | 1 |
Fujiwara, Y | 1 |
Yasuda, T | 1 |
Takiguchi, S | 1 |
Kimura, Y | 1 |
Yano, M | 1 |
Monden, M | 1 |
Liu, L | 1 |
Inoue, H | 1 |
Nakayama, H | 1 |
Kanno, R | 1 |
Kanno, M | 1 |
Chang, YH | 1 |
Bluestone, R | 1 |
Hayashi, T | 1 |
Hasegawa, H | 1 |
Tanaka, G | 1 |
Ohmae, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction[NCT03519074] | Phase 2 | 48 participants (Anticipated) | Interventional | 2016-07-22 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 trial available for oxonic acid and Anasarca
Article | Year |
---|---|
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease | 2016 |
9 other studies available for oxonic acid and Anasarca
Article | Year |
---|---|
Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Chromatography, High Pressure Liquid; Disease M | 2017 |
Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice.
Topics: Animals; Antioxidants; Arthritis, Gouty; Disease Models, Animal; Drugs, Chinese Herbal; Edema; Flavo | 2019 |
Termipaniculatones A-F, chalcone-flavonone heterodimers from Terminthia paniculata, and their protective effects on hyperuricemia and acute gouty arthritis.
Topics: Anacardiaceae; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Chalcone; Dose-Re | 2019 |
Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cecal Neoplasms; Drug Combinations; Edema; Humans; Hypo | 2013 |
The antinociceptive and anti-inflammatory effects of the crude extract of Jatropha isabellei in a rat gout model.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Biomarkers, Pharmacological; Disease | 2013 |
[Weekly administration of paclitaxel as a second-line chemotherapy for advanced and recurrent gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administration Schedu | 2004 |
The endogenous danger signal uric Acid augments contact hypersensitivity responses in mice.
Topics: Animals; B7-2 Antigen; CD40 Antigens; Chlorobenzenes; Dendritic Cells; Dermatitis, Contact; Drug Syn | 2007 |
Adjuvant polyarthritis. VI. Effect of oxonate-induced hyperuricemia on the development of acute inflammation, immune response and adjuvant arthritis.
Topics: Animals; Antibody Formation; Arthritis; Arthritis, Experimental; Cell Line; Diet; Edema; Immunity, C | 1981 |
[A 13-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 1996 |